Across the most recent 1 story covering CyPath® Lung — 100% neutral sentiment, averaging 6/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance
threshold before it is linked here — a story naming this entity only in passing, as
competitive context for an unrelated subject, does not qualify. That threshold exists
because earlier testing surfaced entity pages cluttered with tangential mentions: a story
about two unrelated companies merging could otherwise populate a third company's page
simply because it was named once for comparison, with no real event of its own. The
timeline below reflects genuine milestones and developments specific to this entity,
cross-referenced against the same source-verification standard applied to every story on
this site. Sentiment measures the directional read of each development for this entity
specifically, not the overall tone of the reporting, and impact weights how consequential
a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and
sentiment are derived. See something wrong on this page? Report a data issue.
bioAffinity Technologies reported a record Q2 for its CyPath® Lung noninvasive test, with sales more than doubling year-over-year and physician adoption accelerating. The test, designed to help evaluate indeterminate lung nodules, has now been used nearly 3,000 times across pulmonology and VA settings. The trend underscores the demand for noninvasive early cancer diagnostics in an expanding screening population.